Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)

Submission Date: October 21, 2007

Direct costs are limited to $275,000 over a two-year period, with no more than $200,000 in direct costs allowed in any single year. Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period.

The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases. Investigators who have no prior history of receiving independent NIH funding or no prior history of receiving independent NIH funding in this field are encouraged to apply to this FOA.

For more information, please visit the NIH grants webpage.